Table of Contents
Introduction
The Global Cell and Gene Therapy Market size is expected to be worth around USD 78 Billion by 2032, from USD 13.1 Billion in 2023, growing at a CAGR of 22.6% during the forecast period from 2023 to 2032. In 2023, North America held over 49.6% market share, reaching a revenue total of USD 5.3 Billion.
This sector stands at the forefront of substantial advancements, driven by regulatory approvals, technological innovations, and a shift toward personalized medicine. A key growth driver is the increase in regulatory approvals, which accelerates the market introduction of new therapies. Technological advancements are enhancing the efficacy and accessibility of treatments. Moreover, the growing incidence of genetic disorders and cancers is propelling the demand for these innovative therapies, which are set to transform treatment paradigms.
Nonetheless, the market faces challenges, including the high costs of gene therapy products, which impede broader adoption and accessibility. Complex manufacturing processes and the limited shelf life of these products also present logistical hurdles that must be addressed to efficiently meet the rising demand.
Recent developments within the market include the FDA approval received by Novartis AG in May 2022 for KYMRIAH (Tisagenlecleucel) for treating relapsed or refractory (r/r) follicular lymphoma—its third indication after at least two systemic therapies. This approval is pivotal in expanding treatment options for patients facing this difficult condition.
Another significant development is the collaboration between Biogen Inc. and Scribe Therapeutics, announced in May 2022. This partnership, which includes a USD 15 million investment, aims to develop new gene therapy targets for neurological diseases using CRISPR technology, emphasizing the industry’s dedication to addressing unmet medical needs with advanced technologies.
Looking ahead, the cell and gene therapy market is set for extensive growth and transformation. Ongoing technological progress and strategic partnerships are expected to help overcome current obstacles and unlock the potential for groundbreaking treatments. Continued investment in research and development, supported by a favorable regulatory landscape, is likely to spur further innovation and market growth in this dynamic field.
Key Takeaways
- Market Projections: By 2032, the market is expected to grow from USD 10.7 billion in 2022 to USD 78.0 billion, at a CAGR of 22.6%.
- Market Composition: Cell therapy dominates with a 54.3% market share, transforming medical treatments alongside gene therapy.
- Growth Drivers: The market benefits from increased investments, an expanding clinical pipeline, and enhanced healthcare infrastructure.
- Primary Challenge: High costs of production, stringent regulatory frameworks, and extended durations of clinical studies are major growth impediments.
- Leading Segment: Oncological disorders held the largest market share (32%) in 2022.
- Fastest Growing Segment: Genetic disorders are set to grow rapidly, spurred by increasing cases and supportive government policies.
- Principal End-User: Hospitals are projected to experience the highest growth rate over the forecast period.
- Key Trend: There is a notable increase in global R&D spending and the adoption of innovative therapies.
- Regional Dominance: North America leads with a 49.6% share of market revenue, supported by robust research and regulatory environments.
- Asia-Pacific Growth: This region is poised to capture the largest revenue share in the coming years.
Cell and Gene Therapy Statistics
- Regulatory Approvals: In the first quarter of 2024, the USA, China, and Canada collectively approved two gene therapies and one cell therapy, marking significant regulatory milestones.
- Therapeutic Development: The global landscape for gene, cell, and RNA therapies shows over 4,000 treatments in various development stages, demonstrating robust innovation in the sector.
- Clinical Trials Growth: An 11% increase in the number of therapies entering Phase I clinical trials highlights a growing interest in advancing these therapies through the pipeline.
- Sector Dealmaking: Deal-making activities in the cell and gene therapy sector surged by 34% in early 2024, indicating a vibrant transactional environment.
- Startup Financing: Despite a decrease in the number of transactions, startups in this sector raised $240.1 million in Q1 2024, underscoring ongoing investor confidence.
- Global Approvals: The total number of globally approved gene therapies reached 32 by Q1 2024, with two new approvals during the quarter. Additionally, RNA therapies and non-genetically modified cell therapies have seenband 68 global approvals, respectively.
- CAR-T Cell Therapies: A striking 97% of CAR-T cell therapies under development are targeting various cancer types, showing a strong focus on oncological applications.
- Gene Therapy Pipeline: Of all therapies in development, 2,093 are gene therapies, accounting for 52% of the total pipeline. These advancements are predominantly aimed at oncology, with 52% targeting cancer treatments.
- Non-Genetically Modified Cell Therapies: These therapies total 885 and represent 22% of all therapies under development, indicating significant activity in non-genetic modifications.
- In Vivo Delivery Techniques: The use of in vivo delivery techniques was employed in 42% of gene therapies in the first quarter, showcasing cutting-edge delivery methods.
- RNA Therapy Focus: A significant 80% of RNA therapies under development are targeted at non-oncology diseases, illustrating a broad therapeutic potential beyond cancer.
- Financing Growth: A 34% increase in total financing volume for companies in this sector compared to the previous quarter highlights robust financial backing.
- Startup Transaction Trends: Despite a 33% drop in startup deal transactions, the sector completed 125 deals in Q1 2024, reflecting a still-active deal-making scene.
- Diverse Clinical Trials: Gene therapy trials initiated in Q1 2024 saw 43% targeting non-oncology indications, and 57% of all trials were for non-oncology diseases, indicating a diverse research focus.
- Challenges in Advancement: There was an 11% decrease in therapies reaching the pre-registration stage, signifying potential challenges in advancing therapies to later stages.
- Major Acquisition: The largest acquisition in this quarter was Novo Nordisk’s purchase of Cardior Pharmaceuticals for up to €1 billion, a landmark deal within the industry.
Key Statics: Cell and Gene Therapy
- Funding and Clinical Advancements: The cell and gene therapy sector has experienced a surge in both funding and clinical activity due to increasing interest, demonstrating significant growth in research and development initiatives.
- Global Launches of Therapies: A total of 76 cell and gene therapies were launched worldwide by the end of 2023, representing a doubling of such therapies since 2013. This expansion highlights rapid advancements and broader adoption in the field.
- Complexity of Patient Treatment Journey: The journey for patients undergoing these therapies remains complex and fraught with numerous barriers, underscoring the need for streamlined processes and enhanced patient support mechanisms.
- Spending Trends: In 2023, spending on cell and gene therapies reached $5.9 billion, marking a 38% increase from the previous year. Despite this growth, such spending constitutes only 0.4% of the $1.6 trillion spent globally on medicines, indicating a niche yet growing market segment.
- Future Projections: The future trajectory of the cell and gene therapy sector is marked by uncertainty, with various potential scenarios projected through 2035. This uncertainty calls for strategic foresight and adaptable approaches to address forthcoming challenges and opportunities.
Other Findings
- Funding Deals (2014-2023): In 2023, nearly 100 deals and $3.4 billion in deal value occurred.
- Deal Peaks and Declines: Deals peaked at 127 in 2021, dropped 24% in 2022, and remained flat in 2023 at 96 deals.
- Venture Capital: Later-stage venture capital deals grew in 2023; all deal stages remain above levels seen five years ago.
- Clinical Trial Starts (2013-2023): 3,285 trials started in the last five years, with 631 in 2023.
- Trial Sponsorship: Non-industry trials accounted for 36% of 2023 starts, industry-sponsored trials accounted for 64%.
Therapy Launches by Type
- Transcyte Launch: The first therapy, Transcyte, launched in the U.S. in 1997.
- Early Advanced Therapies: Early products included skin substitutes and cartilage repair products.
- First Gene Therapy: Gendicine launched in China in 2004 for head and neck cancer.
Reimbursement in Europe
- Reimbursement Rates: Wealthier European countries generally reimburse these therapies more readily.
- Western Europe: Average reimbursement rate is 60%, with Germany and France reimbursing over 75% of therapies.
- Luxembourg and Switzerland: Reimburse fewer therapies (42%) despite higher GDP per capita.
Global Spending
- Spending Growth: Global spending reached $5.9 billion in 2023, with a 38% increase from the previous year.
- Annual Growth: Spending has averaged 65% annual growth over the last five years.
- Geographical Spending: 62% of spending is from the U.S., with 38% from other regions. Higher spending in the U.S. reflects broader acceptance and higher uptake.
Other Statistics
- Investment and Funding Dynamics: Global funding for cell and gene therapy research reached approximately $2.3 billion in 2023, indicating strong interest from both public and private sectors in driving forward these innovative treatments.
- Clinical Trials Expansion: The number of clinical trials globally dedicated to cell and gene therapy surpassed 2,900 as of mid-2024, highlighting the intensive research efforts to explore these therapies.
- Therapeutic Development Landscape: Currently, the development pipeline includes 170 gene therapies and 362 cell therapies, reflecting widespread endeavors to leverage these technologies across various diseases.
- FDA Regulatory Approvals: To date, the FDA has approved 25 cell and gene therapies, including seven new approvals in 2023, signifying a quickening pace in regulatory endorsements.
- Manufacturing Capacity Enhancement: Major biotechnology firms have invested over $500 million in the past year to expand manufacturing capabilities, aiming to fulfill increasing demand for these therapies.
- Research Focus Areas: Over 60% of all ongoing research in cell and gene therapies is directed towards cancer and rare genetic disorders, underscoring the primary therapeutic targets of current interventions.
- Success Rates: The transition success rate from Phase I trials to FDA approval for these therapies is about 14%, higher than the average across all pharmaceuticals.
- Academic Contributions: The publication of over 5,000 research articles in peer-reviewed journals in 2023 demonstrates significant academic engagement and progress in this field.
- Venture Capital Trends: Venture capital investments in startups specializing in cell and gene therapies surged by 30% year-over-year, totaling $1.8 billion in 2023.
- Strategic Partnerships and Collaborations: In 2024, more than 120 new partnerships have been established between biotech companies and academic institutions to further cell and gene therapy research.
- Regulatory Framework Enhancements: Regulatory bodies in over 20 countries have implemented new guidelines to streamline the approval processes for these therapies, adapting to the sector’s growth.
- Patient Impact: Around 35,000 patients globally received treatment with commercially available cell and gene therapies in 2023, nearly doubling the patient reach from the previous year.
- Technological Advancements: Technological improvements have reduced the production turnaround time for customized cell therapies from four weeks to just seven days.
- Accessibility and Affordability: Initiatives aimed at reducing gene therapy treatment costs have achieved a 25% reduction in average prices over the past three years.
- Educational Developments: Over 50 new educational programs focusing on cell and gene therapy have been launched worldwide in the last year, preparing a new generation of scientists and clinicians.
- Intellectual Property Milestones: The granting of cell and gene therapy-related intellectual property licenses has increased by 40% year-over-year, indicating strong commercial potential.
- Public Engagement and Perception: Public awareness and acceptance of cell and gene therapies have markedly improved, with over 70% of surveyed individuals in 2024 expressing a positive stance towards these treatments.
Emerging Trends
- Enhanced Regulatory Scrutiny and Safety Protocols: Regulatory bodies, including the FDA and EMA, are intensifying their oversight concerning the safety of CAR-T therapies, particularly focusing on potential risks such as secondary malignancies. This has led to a more cautious adoption of these therapies in clinical settings, especially in areas where safer non-oncology alternatives are available.
- Breakthroughs in Gene Editing Technologies: CRISPR technology has marked a significant milestone with the approval of new therapies for genetic disorders like sickle cell disease and beta thalassemia. These advancements are transformative, offering treatments that address the genetic basis of diseases, enhancing both the precision and efficacy of therapies.
- Manufacturing Process Innovations: The sector is progressing towards more efficient manufacturing techniques, notably in the development of off-the-shelf allogeneic CAR-T therapies. These innovations facilitate quicker and more scalable production compared to traditional patient-specific methods, crucial for meeting growing global demands and reducing costs.
- Increased Investment in Research and Development: A surge in R&D investments is evident within the cell and gene therapy field, reflected by the increasing number of active cell and nucleic acid therapeutic programs. This trend indicates a robust future pipeline and the potential introduction of more groundbreaking therapies into the market.
- Adoption of Outcome-based Pricing Models: In response to escalating therapy costs, the industry is moving towards outcome-based pricing models. These models align therapy prices with the clinical outcomes they achieve, offering a more financially sustainable approach for healthcare providers and insurers and enhancing the accessibility of costly treatments.
Use Cases
- Oncology Advancements: Cell and gene therapies (CGTs), particularly CAR-T cell therapies, are revolutionizing the treatment of cancer, initially focusing on hematological malignancies like lymphoma and leukemia. These therapies are now extending to solid tumors, enhancing the potential for oncology treatments by offering more precise and personalized therapeutic options, thus promising improved patient outcomes with reduced side effects.
- Treatment of Rare Genetic Disorders: Gene therapies are providing groundbreaking treatment opportunities for rare genetic disorders such as Duchenne muscular dystrophy and spinal muscular atrophy. By directly correcting the underlying genetic defects, these therapies not only offer treatment but also potential cures for conditions once considered intractable, giving new hope to affected patients and their families.
- Expanding into Neurodegenerative and Cardiovascular Diseases: The scope of cell and gene therapies is broadening beyond oncology and rare diseases to address complex conditions like neurodegenerative disorders and cardiovascular diseases. The adaptability of these therapies opens up promising new treatment pathways for diseases that are currently underserved by conventional medical approaches.
- Applications in Immunological and Inflammatory Diseases: There is an increasing focus on deploying cell and gene therapies to manage autoimmune and inflammatory diseases. These innovative approaches are poised to offer enhanced efficacy and fewer side effects compared to existing treatments, representing a transformative advance in managing complex immunological and inflammatory ailments and leading to more effective and lasting solutions.
Conclusion
The cell and gene therapy sector is poised for transformative growth, driven by increasing regulatory approvals, technological innovations, and strategic partnerships. Despite facing challenges such as high production costs and complex manufacturing processes, the industry shows robust momentum, supported by a strong pipeline of developments and significant financial investment. The promising advancements in treating oncological and genetic disorders, alongside expanding applications in other complex diseases, highlight the sector’s potential to revolutionize medical treatments. Continued investment and adaptive regulatory frameworks will be crucial in overcoming obstacles and fulfilling the potential of these groundbreaking therapies.
Discuss Your Needs With Our Analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
